evidence table

Inulin Gut Microbiome Randomized Trial Evidence Table

Structured evidence table for Inulin Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Inulin Gut Microbiome Randomized TrialProtocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.2Schöttker B (2026)Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
Inulin Gut Microbiome Randomized TrialIn addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States [].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized TrialClinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura.3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized Trial6 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized Trial1 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population [].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
topicInulin Gut Microbiome Randomized Trial
claimProtocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
evidence level2
citationSchöttker B (2026)
sourceProtocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
topicInulin Gut Microbiome Randomized Trial
claimIn addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States [].
evidence level3
citationKozák Márk (2026)
sourceMigraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
topicInulin Gut Microbiome Randomized Trial
claimClinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura.
evidence level3
citationKozák Márk (2026)
sourceMigraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
topicInulin Gut Microbiome Randomized Trial
claim6 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,].
evidence level3
citationKozák Márk (2026)
sourceMigraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
topicInulin Gut Microbiome Randomized Trial
claim1 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population [].
evidence level3
citationKozák Márk (2026)
sourceMigraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics

Learn next

Related evidence and supplement guides

SupplementAkkermansia MuciniphilaA next-generation gut bacterium that plays a crucial role in strengthening the intestinal mucin...SupplementProbioticsLive beneficial bacteria that support digestive health, immune function, and the gut-brain axis.GuideKefir Gut Microbiome Randomized Trial: What the Evidence SaysKefir Gut Microbiome Randomized Trial has 2 source documents in the current Migaku evidence data...GuideFermented Milk Gut Microbiome Randomized Trial: What the Evidence SaysFermented Milk Gut Microbiome Randomized Trial has 2 source documents in the current Migaku evid...GuideBeta Glucan Gut Microbiome Randomized Trial: What the Evidence SaysBeta Glucan Gut Microbiome Randomized Trial has 2 source documents in the current Migaku evidenc...GuidePrebiotic Gut Microbiome Randomized Trial: What the Evidence SaysPrebiotic Gut Microbiome Randomized Trial has 3 source documents in the current Migaku evidence...RankingBest Probiotics for Gut Health: 2026 Evidence Review & RankingsWe analyzed over 25 probiotic brands to find the best formulations containing scientifically val...RankingBest Gut Health Supplements 2026: Ranked by EvidenceThe gut health supplement market is full of overclaimed products. These have the strongest evide...

Source documents

  1. Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
  2. Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics